The historic list of the first 10 drug prices negotiated for Medicare may emerge as a double-edged sword in pending litigation between the Biden administration and pharmaceutical industry, intensifying the debate over the legal future of the program.
The US government’s Thursday unveiling of lowered prescription drug costs from the first cycle of the Medicare Drug Price Negotiation Program touted billions of dollars in savings for government spending and beneficiary costs, after the landmark Inflation Reduction Act allowed the US to set the prices of some of the most expensive and widely used drugs covered under Medicare.